Polmacoxib

Summary

Polmacoxib (CHEMBL166863) is a phase-3 clinical-stage small molecule (ATC M01AH07); indicated across 4 conditions including osteoarthritis, hip and rheumatic disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: M01AH07
• Indications: 4 conditions
• Clinical trials: 8
• Chemistry: 361.4 Da · C18H16FNO4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL166863
Name	Polmacoxib
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9841854
ATC	M01AH07
Molecular formula	C18H16FNO4S
Molecular weight	361.4
InChIKey	IJWPAFMIFNSIGD-UHFFFAOYSA-N

SMILES: CC1(C(=O)C(=C(O1)C2=CC=C(C=C2)S(=O)(=O)N)C3=CC(=CC=C3)F)C

IUPAC name: 4-[3-(3-fluorophenyl)-5,5-dimethyl-4-oxofuran-2-yl]benzenesulfonamide

Also known as: CG-100649, CG100649, Polmacoxib, POLMACOXIB

Patent coverage: 304 distinct patent families (625 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prostaglandin G/H synthase 1.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P22437	8.52	IC50	3	nM	CHEMBL_ACT_18940858

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
osteoarthritis, hip	3	MONDO:0006629	EFO:1000786
rheumatic disorder	3	MONDO:0005554	EFO:0005755
osteoarthritis	3	MONDO:0005178	MONDO:0005178
osteoarthritis, knee	2	MONDO:0005416	EFO:0004616

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE1	5
PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01765296	PHASE3	COMPLETED	Phase III Study of CG100649 in Osteoarthritis Patients
NCT00530452	PHASE2	UNKNOWN	Phase II Study of CG100649 for Primary Osteoarthritis in Male Subjects
NCT01341405	PHASE2	COMPLETED	Study of CG100649 Versus Celecoxib in Osteoarthritis Patients
NCT00780325	PHASE1	TERMINATED	Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition
NCT01154764	PHASE1	COMPLETED	Trial for Studying Pharmacokinetic Effects of Ketoconazole on CG100649
NCT01154790	PHASE1	COMPLETED	Phase I Study on Multiple Oral Dosing of CG100649
NCT03775629	PHASE1	COMPLETED	Drug-Drug Interaction Study of CG100650 in Healthy Volunteers
NCT05370716	PHASE1	COMPLETED	Drug-Drug Interaction Study of CG-651 in Healthy Volunteer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).